您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2025, Vol. 63 ›› Issue (5): 12-17.doi: 10.6040/j.issn.1671-7554.0.2024.0771

• 重点专题——动脉桥在冠脉旁路移植中的应用 • 上一篇    

解剖完全再血管化是冠心病外科治疗的新策略

陈绪军1,申林2,陈军3,于涛4,曹广庆5,肖飞6   

  1. 1.华中科技大学同济医学院武汉市第一医院心外科, 湖北 武汉 430022;2.重庆医科大学附属第二医院心胸外科, 重庆 401336;3.华中科技大学同济医学院附属同济医院心血管外科, 湖北 武汉 430022;4.四川省人民医院心脏外科中心, 四川 成都 610072;5.山东大学齐鲁医院心外科, 山东 济南 250012;6.广东省人民医院心外科, 广东 广州 510080
  • 发布日期:2025-05-07
  • 通讯作者: 陈绪军. E-mail:chenstan@163.com

Anatomic complete revascularization is a new strategy of surgical treatment for coronary heart disease

CHEN Xujun1, SHEN Lin2, CHEN Jun3, YU Tao4, CAO Guangqing5, XIAO Fei6   

  1. 1. Department of Cardiac Surgery, Wuhan First Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China;
    2. Department of Cardio-Thoracic Surgery, The Second Affiliated Hospital of Chonging Medical University, Chongqing 401336, China;
    3. Department of Cardiac Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China;
    4. Cardiac Surgery Center, Sichuan Provincial Peoples Hospital, Chengdu 610072, Sichuan, China;
    5. Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    6. Department of Cardiac Surgery, Guangdong Provincial Peoples Hospital, Guangzhou 510080, Guangdong, China
  • Published:2025-05-07

PDF (PC)

105

摘要： 冠状动脉旁路移植术(coronary artery bypass grafting, CABG)中完全再血管化(complete revascularization, CR)近来受到越来多的重视,CR分为解剖完全再血管化(anatomic complete revascularization, ACR)与功能完全再血管化(functional complete revascularization, FCR)。多项研究证实CR的CABG患者围手术期安全、中远期效果更好。近来全球多中心随机对照临床试验ISCHEMIA研究证实,对于稳定型缺血性心脏病,ACR与FCR均比非完全再血管化和药物保守治疗更能改善稳定性心绞痛患者心绞痛相关的健康状况、生活质量,减少心脏死亡与心肌梗死的发生,并改善中-长期临床效果,而且ACR明显优于FCR。ACR是CABG的新治疗策略,尽管存在亟待解决的问题,但可望为改善CABG疗效提供新的思路并在全动脉CABG、慢性缺血性心肌病患者CABG以及冠脉杂交手术中产生广泛的应用前景。

关键词: 冠心病, 冠状动脉旁路移植术, 完全再血管化, 解剖完全再血管化

Abstract: Complete revascularization(CR)has received increasing attention in coronary artery bypass grafting(CABG)and is categorized as anatomic complete revascularization(ACR)and functional complete revascularization(FCR). Multiple clinical trials validated that CR was associated with improved mid-term and long-term clinical outcomes in CABG. A recent randomized controlled multicenter trial(ISCHEMIA study)showed that both ACR and FCR in CABG led to improved angina-related health status and life quality, reduced incidence of cardiac death and myocardial infarction, and improved mid-term and long-term outcomes compared with incomplete revascularization and conservative management in patients with stable ischemic heart disease, more pronounced with ACR than FCR. Although there are urgent problems to be solved, ACR, as a new surgical strategy, might offer a new perspective for improving safety and efficacy of CABG and promise to be widely used in total arterial CABG, surgical treatment of chronic ischemic cardiomyopathy, and hybrid coronary revascularization.

Key words: Coronary heart disease, Coronary artery bypass grafting, Complete revascularization, Anatomic complete revascularization

中图分类号: 

  • R654
[1] Gaba P, Gersh BJ, Ali ZA, et al. Complete versus incomplete coronary revascularization: definitions, assessment and outcomes[J]. Nat Rev Cardiol, 2021, 18(3): 155-168.
[2] Ali ZA, Horst J, Gaba P, et al. Standardizing the definition and analysis methodology for complete coronary artery revascularization[J]. J Am Heart Assoc, 2021, 10(9): e020110. doi: 10.1161/JAHA.120.020110
[3] Belyayev L, Stock EM, Hattler B, et al. Complete coronary revascularization and outcomes in patients who underwent coronary artery bypass grafting: insights from the REGROUP trial[J]. Am J Cardiol, 2024, 217: 127-135. doi:10.1016/j.amjcard.2024.01.015
[4] Shintomi S, Saito S, Hamasaki A, et al. Propensity score-matched comparison of total arterial off- and on-pump coronary artery bypass with complete revascularization[J]. Heart Vessels, 2024, 39(2): 175-184.
[5] Aboul-Hassan SS, Awad AK, Stankowski T, et al. Impact of incomplete revascularization on long-term survival based on revascularization strategy[J]. Ann Thorac Surg, 2024, 118(3): 605-614.
[6] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2): 87-165.
[7] Bianco V, Kilic A, Aranda-Michel E, et al. Complete revascularization during coronary artery bypass grafting is associated with reduced major adverse events[J]. J Thorac Cardiovasc Surg, 2023, 166(1): 104-113.
[8] Schaefer A, Conradi L, Schneeberger Y, et al. Clinical outcomes of complete versus incomplete revascularization in patients treated with coronary artery bypass grafting: insights from the TiCAB trial[J]. Eur J Cardiothorac Surg, 2020: ezaa330. doi:10.1093/ejcts/ezaa330
[9] Diegeler A, Börgermann J, Kappert U, et al. Five-year outcome after off-pump or on-pump coronary artery bypass grafting in elderly patients[J]. Circulation, 2019, 139(16): 1865-1871.
[10] Sohn SH, Kang Y, Kim JS, et al. Impact of functional vs anatomic complete revascularization in coronary artery bypass grafting[J]. Ann Thorac Surg, 2023, 115(4): 905-912.
[11] Sakata T, De La Pena C, Ohira S. Functional or anato-mical completeness of revascularization after coronary artery bypass grafting[J]. Ann Thorac Surg, 2023, 116(4): 862.
[12] Group ITR, Maron DJ, Hochman JS, et al. International study of comparative health effectiveness with medical and invasive approaches(ISCHEMIA)trial: rationale and design[J]. Am Heart J, 2018, 201: 124-135. doi:10.1016/j.ahj.2018.04.011
[13] Mavromatis K, Jones PG, Ali ZA, et al. Complete revascularization and angina-related health status in the ISCHEMIA trial[J]. J Am Coll Cardiol, 2023, 82(4): 295-313.
[14] Stone GW, Ali ZA, O’Brien SM, et al. Impact of complete revascularization in the ISCHEMIA trial[J]. J Am Coll Cardiol, 2023, 82(12): 1175-1188.
[15] Mehaffey JH, Hawkins RB. Commentary: At the surgeon’s discretion: complete revascularization is best[J]. J Thorac Cardiovasc Surg, 2023, 166(1): 118-119.
[16] Dimitriadis K, Pyrpyris N, Tsioufis K. Functional vs anatomical complete revascularization: is there an “ISCHEMIA” of FFR?[J]. J Am Coll Cardiol, 2024, 83(4): e35. doi:10.1016/j.jacc.2023.10.048
[17] Ren J, Royse C, Tian DH, et al. Survival of multiple arterial grafting in diabetic populations: a 20-year national experience[J]. Eur J Cardiothorac Surg, 2023, 63(6): ezad091. doi:10.1093/ejcts/ezad091
[18] Rocha RV, Tam DY, Karkhanis R, et al. Long-term outcomes associated with total arterial revascularization vs non-total arterial revascularization[J]. JAMA Cardiol, 2020, 5(5): 507-514.
[19] Taggart DP, Gaudino MF, Gerry S, et al. Effect of total arterial grafting in the Arterial Revascularization Trial[J]. J Thorac Cardiovasc Surg, 2022, 163(3): 1002-1009.
[20] Sabik JF 3rd, Mehaffey JH, Badhwar V, et al. Multiarterial vs single-arterial coronary surgery: 10-year follow-up of 1 million patients[J]. Ann Thorac Surg, 2024, 117(4): 780-788.
[21] Gaudino M, Puskas JD, Di Franco A, et al. Three ar-terial grafts improve late survival: a meta-analysis of propensity-matched studies[J]. Circulation, 2017, 135(11): 1036-1044.
[22] Ren J, Tian DH, Gaudino M, et al. Survival benefit of multiple arterial revascularization with and without supp-lementary saphenous vein graft[J]. J Am Heart Assoc, 2023, 12(22): e031986. doi:10.1161/JAHA.123.031986
[23] Gaudino MFL, Sandner S, Bonalumi G, et al. How to build a multi-arterial coronary artery bypass programme: a stepwise approach[J]. Eur J Cardiothorac Surg, 2020, 58(6): 1111-1117.
[24] Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy[J]. N Engl J Med, 2016, 374(16): 1511-1520.
[25] Bakaeen FG, Gaudino M, Whitman G, et al. 2021: the American Association for Thoracic Surgery Expert Consensus Document: coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure[J]. J Thorac Cardiovasc Surg, 2021, 162(3): 829-850.
[26] Iacona GM, Bakhos JJ, Tong MZ, et al. Coronary artery bypass grafting in left ventricular dysfunction: when and how[J]. Curr Opin Cardiol, 2023, 38(6): 464-470.
[27] 刘达兴, 陈绪军, 郑宝石, 等. 体外循环下全动脉冠状动脉旁路移植治疗左室功能低下冠心病多中心临床观察[J]. 中华医学杂志, 2020, 100(18): 1390-1395. LIU Daxing, CHEN Xujun, ZHENG Baoshi, et al. On-pump total arterial revascularization in coronary artery disease patients with left ventricular dysfunction: a multi-center retrospective study[J]. National Medical Journal of China, 2020, 100(18): 1390-1395.
[28] Nakae M, Kainuma S, Toda K, et al. Impact of complete revascularization in coronary artery bypass grafting for ischemic cardiomyopathy[J]. JTCVS Open, 2023, 15: 211-219. doi:10.1016/j.xjon.2023.04.008
[29] Fang HY, Fang YN, Chen YC, et al. The impact of complete revascularization in symptomatic severe left ventricular dysfunction between coronary artery bypass graft and percutaneous coronary intervention[J]. Cardiol Res Pract, 2023, 2023: 9226722. doi:10.1155/2023/9226722
[30] Fremes SE, Marquis-Gravel G, Gaudino MFL, et al. STICH3C: rationale and study protocol[J]. Circ Cardiovasc Interv, 2023, 16(8): e012527. doi:10.1161/CIRCINTERVENTIONS.122.012527
[31] Mavioglu I. Minimally invasive off-pump anaortic complete arterial coronary artery bypass: how to do it?[J]. Innovations, 2023, 18(4): 376-379.
[32] Stähli BE, Varbella F, Linke A, et al. Timing of complete revascularization with multivessel PCI for myocardial infarction[J]. N Engl J Med, 2023, 389(15): 1368-1379.
[33] Guyton RA, Halkos ME. Benefit of complete anatomic revascularization in ISCHEMIA: reprise of a familiar theme[J]. J Am Coll Cardiol, 2024, 83(4): e37. doi:10.1016/j.jacc.2023.10.047
[34] 陈绪军, 张建, 李伟栋, 等. 2023 年欧洲心胸外科协会和美国胸外科医师协会《冠状动脉旁路移植术旁路血管选择专家共识》解读[J]. 中华外科杂志, 2024, 62(1): 44-48. CHEN Xujun, ZHANG Jian, LI Weidong, et al. Interpretation on Expert systematic review on the choice of conduits for coronary artery bypass grafting endorsed by the European Association for Cardio Thoracic Surgery and the Society of Thoracic Surgeons in 2023[J]. Chinese Journal of Surgery, 2024, 62(1): 44-48.
[35] Kaya IC, Bulut HI, Candelario K, et al. Complete surgical revascularization after NSTEMI and unstable angina in patients with multivessel coronary artery disease: institutional experience[J]. Asian Cardiovasc Thorac Ann, 2023, 31(8): 675-681.
[1] 陈绪军,何国伟. 着力进一步推进动脉桥在我国冠心病冠脉旁路移植术中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 1-5.
[2] 张熙伟,任琳玮,张辉,张歆杰,刘伟国,王东. 左胸廓内动脉联合桡动脉行冠状动脉旁路移植术早期临床疗效[J]. 山东大学学报 (医学版), 2024, 62(3): 39-46.
[3] 张恒哲,侯晓慧,Arezou Bikdeli,李大庆. 152例非急性心肌梗死患者完全血运重建介入治疗后疲劳程度的影响因素[J]. 山东大学学报 (医学版), 2023, 61(7): 47-54.
[4] 韩闯,程传龙,李春雨,刘盈,房启迪,崔峰,杨淑霞,韩鹏,李秀君. 气温日较差对淄博市冠心病入院人数的短期影响[J]. 山东大学学报 (医学版), 2023, 61(4): 111-118.
[5] 谢佳莹,祁佳,宋铭,李育林,王迪,贾旭,张薇,钟明,尚嫄嫄. 血清蛋白质β-折叠水平与冠心病的相关性[J]. 山东大学学报 (医学版), 2022, 60(1): 21-26.
[6] 李云霞,李洪凯,马韫韬,于媛媛,孙晓茹,刘新辉, 司书成,侯蕾,袁同慧,刘璐,李文超,薛付忠,刘言训. 基于两样本孟德尔随机化的身高和冠心病风险之间因果关系[J]. 山东大学学报 (医学版), 2020, 58(5): 107-114.
[7] 刘聪聪,陈晓璐,司书成,王博洁,李云霞,李文超,袁同慧,薛付忠. 山东省人群血清尿酸变异性与冠心病发病风险的关系[J]. 山东大学学报 (医学版), 2020, 58(12): 109-116.
[8] 李明卓,孙秀彬,王春霞,杨洋,刘新辉,刘言训,薛付忠,袁中尚. 血脂正常人群HDL-C纵向变化与冠心病的关联性分析:一项回顾性队列研究[J]. 山东大学学报 (医学版), 2019, 57(8): 110-116.
[9] 林伟强,王春霞,李明卓,孙秀彬,刘言训,薛付忠,袁中尚. 中老年人血压变化轨迹与冠心病发病的关系[J]. 山东大学学报 (医学版), 2019, 57(4): 106-112.
[10] 刘新辉,李洪凯,李明卓,于媛媛,司书成,侯蕾,刘璐,李文超,袁同慧,李云霞,周宇畅,薛付忠. 腰围和冠心病因果关系的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2019, 57(11): 103-109.
[11] 王春霞,许艺博,杨宁,夏冰,王萍,薛付忠. 基于健康管理队列的冠心病风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 66-71.
[12] 叶聪. 冠状动脉旁路移植术后桡动脉桥血管通畅率的影响因素分析[J]. 山东大学学报（医学版）, 2016, 54(8): 34-38.
[13] 屈庆喜, 赵鑫, 孙文宇, 宋光民, 孟祥斌, 毕研文. 同期冠状动脉旁路移植术加颈动脉内膜剥脱术治疗冠心病合并颈动脉狭窄的疗效[J]. 山东大学学报（医学版）, 2015, 53(5): 71-74.
[14] 刘天骄, 郭媛, 李婷婷, 张建宁, 李俊, 张鹏. 血清CTRP9、APN水平与急性冠脉综合征的相关性[J]. 山东大学学报（医学版）, 2014, 52(9): 58-62.
[15] 姜红梅1，2，陈文强1. 老年冠心病心衰患者运动康复治疗中心理干预的临床意义[J]. 山东大学学报（医学版）, 2014, 52(4): 85-88.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发